Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans.

The presence and biological significance of circulating glycated insulin has been evaluated by high-pressure liquid chromatography (HPLC), electrospray ionization mass spectrometry (ESI-MS), radioimmunoassay (RIA), receptor binding, and hyperinsulinemic-euglycemic clamp techniques. ESI-MS analysis of an HPLC-purified plasma pool from four male type 2 diabetic subjects (HbA(1c) 8.1 +/- 0.2%, plasma glucose 8.7 +/- 1.3 mmol/l [means +/- SE]) revealed two major insulin-like peaks with retention times of 14-16 min. After spectral averaging, the peak with retention time of 14.32 min exhibited a prominent triply charged (M+3H)(3+) species at 1,991.1 m/z, representing monoglycated insulin with an intact M(r) of 5,970.3 Da. The second peak (retention time 15.70 min) corresponded to native insulin (M(r) 5,807.6 Da), with the difference between the two peptides (162.7 Da) representing a single glucitol adduct (theoretical 164 Da). Measurement of glycated insulin in plasma of type 2 diabetic subjects by specific RIA gave circulating levels of 10.1 +/- 2.3 pmol/l, corresponding to approximately 9% total insulin. Biological activity of pure synthetic monoglycated insulin (insulin B-chain Phe(1)-glucitol adduct) was evaluated in seven overnight-fasted healthy nonobese male volunteers using two-step euglycemic-hyperinsulinemic clamps (2 h at 16.6 micro g x kg(-1) x min(-1), followed by 2 h at 83.0 micro g x kg(-1) x min(-1); corresponding to 0.4 and 2.0 mU x kg(-1) x min(-1)). At the lower dose, the exogenous glucose infusion rates required to maintain euglycemia during steady state were significantly lower with glycated insulin (P < 0.01) and approximately 70% more glycated insulin was required to induce a similar rate of insulin-mediated glucose uptake. Maximal responses at the higher rates of infusion were similar for glycated and control insulin. Inhibitory effects on endogenous glucose production, insulin secretion, and lipolysis, as indicated by measurements of C-peptide, nonesterified free fatty acids, and glycerol, were also similar. Receptor binding to CHO-T cells transfected with human insulin receptor and in vivo metabolic clearance revealed no differences between glycated and native insulin, suggesting that impaired biological activity is due to a postreceptor effect. The present demonstration of glycated insulin in human plasma and related impairment of physiological insulin-mediated glucose uptake suggests a role for glycated insulin in glucose toxicity and impaired insulin action in type 2 diabetes.

[1]  O. Wieland,et al.  Preparation and biological properties of glycosylated insulin , 1979, FEBS letters.

[2]  L. Orci.  A portrait of the pancreatic B-Cell , 1974, Diabetologia.

[3]  P. Flatt,et al.  Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture. , 1997, The Journal of endocrinology.

[4]  R. DeFronzo,et al.  Glucose Toxicity , 1990, Diabetes Care.

[5]  A. Atkinson,et al.  Influence of growth hormone on glucose-glucose 6-phosphate cycle and insulin action in normal humans. , 1992, The American journal of physiology.

[6]  B. Gallwitz,et al.  GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro , 2000, Regulatory Peptides.

[7]  J. Schrezenmeir,et al.  Biological activity of GLP-1-analogues with N-terminal modifications , 1999, Regulatory Peptides.

[8]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[9]  P. Højrup,et al.  Identification of the site of glycation of human insulin , 1996, Peptides.

[10]  R. DeFronzo,et al.  Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. , 1983, The American journal of physiology.

[11]  T. Blundell,et al.  Receptor-binding region of insulin , 1976, Nature.

[12]  A. Jenkins,et al.  Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. , 1997, Diabetes reviews.

[13]  G. Bailin,et al.  Reaction of rabbit skeletal myosin with D‐glucose 6‐phosphate , 1996, Biochemistry and molecular biology international.

[14]  S. Grundy,et al.  Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes , 1985, Diabetologia.

[15]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[16]  P. Flatt,et al.  Glycation of Insulin in the Islets of Langerhans of Normal and Diabetic Animals , 1996, Diabetes.

[17]  S. Lenzen,et al.  Frontiers of insulin secretion and pancreatic B-cell research , 1994 .

[18]  R. Blakytny,et al.  Glycation (non-enzymic glycosylation) inactivates glutathione reductase. , 1992, The Biochemical journal.

[19]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[20]  J. McGarry,et al.  Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.

[21]  I. Waddell,et al.  Identification, purification and genetic deficiencies of the glucose-6-phosphatase system transport proteins , 2005, European Journal of Pediatrics.

[22]  H. Kaneto,et al.  Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells , 1999, Diabetologia.

[23]  S.-M. Kim,et al.  Glycation impairs high-density lipoprotein function , 2000, Diabetologia.

[24]  H. McNulty,et al.  Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. , 2000, Biochimica et biophysica acta.

[25]  J. Sykes,et al.  Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). , 1981, Analytical biochemistry.

[26]  T. Yamaoka,et al.  Inactivation of Cu,Zn-Superoxide Dismutase by In Vitro Glycosylation and in Erythrocytes of Diabetic Patients , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[27]  E. Ganea,et al.  Inactivation of glucose-6-phosphate dehydrogenase by glycation. , 1994, Biochemical Society transactions.

[28]  P. Flatt,et al.  Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues. , 2000, The Journal of endocrinology.

[29]  M. Brownlee.  The pathological implications of protein glycation. , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[30]  R. Steele,et al.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method. , 1956, The American journal of physiology.

[31]  Matschinsky Fm.  Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. , 1996 .

[32]  P. Flatt,et al.  Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes , 1997, Proceedings of the Nutrition Society.

[33]  C. Bailey,et al.  Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice , 1981, Diabetologia.

[34]  J. Holst,et al.  Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity , 1998, Diabetologia.

[35]  Ukpds,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes , 2002 .

[36]  L. Mandarino,et al.  Dose-response characteristics for effects of insulin on production and utilization of glucose in man. , 1981, The American journal of physiology.

[37]  J. Conlon,et al.  Glycation of glucagon-like peptide-1(7–36)amide: characterization and impaired action on rat insulin secreting cells , 1998, Diabetologia.

[38]  M. Takahashi,et al.  In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. , 1995, Biochemistry.

[39]  S. Fujii,et al.  Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. , 1987, The Journal of biological chemistry.

[40]  F M Matschinsky,et al.  A Lesson in Metabolic Regulation Inspired by the Glucokinase Glucose Sensor Paradigm , 1996, Diabetes.

[41]  R. Steele,et al.  ON THE HORMONAL REGULATION OF CARBOHYDRATE METABOLISM; STUDIES WITH C14 GLUCOSE. , 1963, Recent progress in hormone research.

[42]  P. Tessari,et al.  Reduced In Vivo Biological Activity of In Vitro Glycosylated Insulin , 1988, Diabetes.

[43]  A. Atkinson,et al.  Underestimation of glucose turnover determined using [6-3H]glucose tracer in non-steady state , 1990, Diabetologia.

[44]  T. Lyons,et al.  Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. , 1993, The Journal of clinical investigation.

[45]  P. Traldi,et al.  Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG , 2000, Journal of the American Society for Mass Spectrometry.

[46]  Michael Somogyi,et al.  Determination of blood sugar. , 1945 .

[47]  A. Gugliucci,et al.  Polyclonal immunoglobulin M: location of glycation sites. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[48]  J. Stevens.  Determination of glucose by an automatic analyser. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[49]  R. Rizza,et al.  Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. , 1986, The New England journal of medicine.

[50]  P. Flatt,et al.  Glycation of insulin results in reduced biological activity in mice , 1997, Acta Diabetologica.